Charles Schwab Investment Management Inc. cut its position in InMode Ltd. (NASDAQ:INMD - Free Report) by 13.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 183,777 shares of the healthcare company's stock after selling 29,332 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.22% of InMode worth $3,069,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans purchased a new position in InMode in the third quarter valued at about $201,000. Intech Investment Management LLC acquired a new position in shares of InMode in the 3rd quarter valued at approximately $526,000. D.A. Davidson & CO. boosted its stake in shares of InMode by 10.5% during the 3rd quarter. D.A. Davidson & CO. now owns 41,278 shares of the healthcare company's stock valued at $700,000 after buying an additional 3,915 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of InMode during the third quarter worth approximately $1,104,000. Finally, Townsquare Capital LLC bought a new stake in shares of InMode in the third quarter worth $202,000. 68.04% of the stock is owned by institutional investors and hedge funds.
InMode Price Performance
Shares of INMD stock traded up $0.04 on Monday, hitting $17.74. 1,870,219 shares of the stock traded hands, compared to its average volume of 1,164,323. The company's fifty day moving average is $18.34 and its 200 day moving average is $17.79. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $21.76. The company has a market capitalization of $1.23 billion, a PE ratio of 7.55 and a beta of 2.08.
Wall Street Analysts Forecast Growth
A number of research firms have commented on INMD. Barclays increased their price objective on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, InMode has an average rating of "Hold" and an average target price of $22.25.
View Our Latest Report on INMD
About InMode
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Read More
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
